Payment overview · 2025
General Payments
$346.32
17 reported records · 8 companies
Healthcare provider profile · identity verified
Kabir Kumar Das, MD
Allopathic & Osteopathic Physicians|Internal Medicine · STOCKBRIDGE, GA · NPI 1699955377
Verified facts
What the public records show
CMS Open Payments records show Kabir Kumar Das, MD received $346.32 in general payments during 2025 across 17 reported records.
Novo Nordisk Inc accounted for 52.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Shingrix.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 171 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $183.04 | 52.9% | 9 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $46.63 | 13.5% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.46 | 6.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.78 | 6.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.77 | 6.0% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $19.59 | 5.7% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.65 | 4.8% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$15.40 | 4.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $330.05 | 16 |
| Education | $16.27 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $106.55 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $90.28 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $76.49 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $27.97 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $23.46 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $23.46 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $20.78 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $20.78 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.77 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $19.59 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.66 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.66 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $15.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 144 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 67 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 171 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 32 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
32 | 22 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
67 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
67 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
171 | 40 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
144 | 35 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 463 | 148 |
| Amlodipine Besylate | Amlodipine Besylate | 444 | 146 |
| Levothyroxine Sodium | Levothyroxine Sodium | 436 | 111 |
| Pantoprazole Sodium | Pantoprazole Sodium | 302 | 93 |
| Gabapentin | Gabapentin | 282 | 95 |
| Metformin Hcl | Metformin Hcl | 274 | 82 |
| Lisinopril | Lisinopril | 270 | 75 |
| Omeprazole | Omeprazole | 234 | 83 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 225 | 63 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 210 | 69 |
| Hydrochlorothiazide | Hydrochlorothiazide | 207 | 62 |
| Pravastatin Sodium | Pravastatin Sodium | 196 | 52 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 185 | 64 |
| Ozempic | Semaglutide | 171 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 168 | 45 |
| Fluticasone Propionate | Fluticasone Propionate | 161 | 78 |
| Losartan Potassium | Losartan Potassium | 160 | 49 |
| Eliquis | Apixaban | 144 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 144 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 144 | 48 |
| Clopidogrel | Clopidogrel Bisulfate | 119 | 39 |
| Simvastatin | Simvastatin | 110 | 38 |
| Tramadol Hcl | Tramadol Hcl | 110 | 41 |
| Fluoxetine Hcl | Fluoxetine Hcl | 107 | 30 |
| Carvedilol | Carvedilol | 102 | 31 |
| Glimepiride | Glimepiride | 100 | 26 |
| Potassium Chloride | Potassium Chloride | 98 | 23 |
| Furosemide | Furosemide | 91 | 33 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 91 | 27 |
| Valsartan | Valsartan | 87 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 86 | 22 |
| Trazodone Hcl | Trazodone Hcl | 85 | 30 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 83 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 79 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 79 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 78 | 28 |
| Allopurinol | Allopurinol | 76 | 23 |
| Montelukast Sodium | Montelukast Sodium | 76 | 25 |
| Methylprednisolone | Methylprednisolone | 73 | 52 |
| Prednisone | Prednisone | 72 | 37 |
| Alprazolam | Alprazolam | 68 | 20 |
| Glipizide Er | Glipizide | 67 | 18 |
| Jardiance | Empagliflozin | 67 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 67 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 67 | 13 |
| Eszopiclone | Eszopiclone | 65 | 17 |
| Famotidine | Famotidine | 64 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 63 | 23 |
| Meloxicam | Meloxicam | 62 | 21 |
| Alendronate Sodium | Alendronate Sodium | 60 | 21 |
| Farxiga | Dapagliflozin Propanediol | 60 | 14 |
| Buspirone Hcl | Buspirone Hcl | 59 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 59 | 16 |
| Pregabalin | Pregabalin | 58 | 20 |
| Atenolol | Atenolol | 57 | 19 |
| Lovastatin | Lovastatin | 56 | 15 |
| Sertraline Hcl | Sertraline Hcl | 56 | 17 |
| Januvia | Sitagliptin Phosphate | 54 | suppressed |
| Fluconazole | Fluconazole | 52 | 21 |
| Amoxicillin | Amoxicillin | 51 | 40 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 50 | 12 |
| Ibuprofen | Ibuprofen | 49 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 49 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 49 | 23 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 48 | 17 |
| Mounjaro | Tirzepatide | 48 | suppressed |
| Myrbetriq | Mirabegron | 48 | 12 |
| Memantine Hcl | Memantine Hcl | 47 | 15 |
| Glipizide | Glipizide | 46 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 45 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 44 | 16 |
| Metformin Hcl Er | Metformin Hcl | 44 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 42 | 14 |
| Linzess | Linaclotide | 41 | 17 |
| Nifedipine Er | Nifedipine | 40 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | suppressed |
| Spironolactone | Spironolactone | 38 | suppressed |
| Trulicity | Dulaglutide | 38 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 37 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 37 | 12 |
| Celecoxib | Celecoxib | 36 | 16 |
| Doxepin Hcl | Doxepin Hcl | 36 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 35 | 12 |
| Lorazepam | Lorazepam | 35 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 27 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 34 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 33 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 32 | 11 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 32 | 22 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 31 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Levetiracetam | Levetiracetam | 31 | 11 |
| Sucralfate | Sucralfate | 31 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 18 |
| Chlorthalidone | Chlorthalidone | 30 | 11 |
| Clonazepam | Clonazepam | 30 | suppressed |
| Ezetimibe | Ezetimibe | 30 | 12 |
| Donepezil Hcl | Donepezil Hcl | 29 | 14 |
| Valacyclovir | Valacyclovir Hcl | 28 | 12 |
| Verapamil Er | Verapamil Hcl | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | 15 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 25 | 14 |
| Ketoconazole | Ketoconazole | 25 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 22 |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 23 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 23 | suppressed |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Levemir Flexpen | Insulin Detemir | 22 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 21 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 21 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Tradjenta | Linagliptin | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 14 | suppressed |
| Azithromycin | Azithromycin | 14 | 13 |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | 12 |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Acetazolamide | Acetazolamide | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Prolia | Denosumab | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
| Zaleplon | Zaleplon | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $346.32 · 17 records | Novo Nordisk Inc | AREXVY, CAPVAXIVE, ELIQUIS, GARDASIL 9, JARDIANCE, Kerendia, MINIMED 780G, MOUNJARO, NURTEC ODT, Ozempic, Rybelsus, SHINGRIX, Senza, Wegovy, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error